



## DEPOSITARY RECEIPTS

### NEW DR ANNOUNCEMENT

November 25, 2015

#### Kitov Pharmaceuticals Holdings Ltd.

Kitov Pharmaceuticals Holdings is a biopharmaceutical company based in Israel. The Company is engaged in the development of non-steroidal anti-inflammatory drugs that treat the pain of osteoarthritis without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes. The Company provides the simultaneous treatment of two clinical conditions through the development of combination drugs. The Company's operations are focused on two late stage drugs: KIT-301, Naproxen combined with anti-hypertension and KIT-302, Celecoxib combined with anti-hypertension.

<b>DR Name:</b>	Kitov Pharmaceuticals
<b>Effective Date:</b>	November 25, 2015
<b>Country of Incorporation:</b>	Israel
<b>Exchange:</b>	NASDAQ Stock Market
<b>Type of ADR Program:</b>	Sponsored - Level III
<b>Ticker Symbol:</b>	KTOV
<b>CUSIP Number:</b>	49803V107
<b>Ratio (DR:ORD):</b>	1 : 20
<b>Underlying Share Description:</b>	Ordinary
<b>Industry Classification:</b>	Pharma. & Biotech.
<b>Custodian(s) :</b>	Bank Leumi Le-Israel

To learn more about ADRs and issuer programs, please call our marketing desks:

#### New York

Ravi Davis  
Adrdesk@bnymellon.com  
Tel: 212 815 2267

#### Hong Kong

Herston Powers  
Vice President  
herston.powers@bnymellon.com  
Tel: 65 6432 0281

#### London

Jacek Jankowski  
DR Broker Liaison  
jacek.jankowski@bnymellon.com  
Tel: 442071637427

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contain herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.